DR info

Clinical trials : 112 / Drugs : 155 - (DrugBank : 55) / Drug target genes : 25 - Drug target pathways : 97

Drugs and their primary sponsors and trial info

13 valent conjugated pneumococcal vaccine
   Medical University of South Carolina
      2015   Early Phase 1   NCT03039491   United States;
ACETYL- L- CARNITINE
   SIGMA-TAU
      2006   -   EUCTR2005-004665-42-IT   Italy;
AKCEA-ANGPTL3-LRX
   Akcea Therapeutics
      2018   Phase 2   NCT03514420   United States;
ATV
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom;
AZT/3TC
   University Hospital Birmingham
      2005   Phase 4   EUCTR2005-004021-26-GB   United Kingdom;
Abacavir
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
Abacavir 300mg twice daily
   Gilead Sciences
      2003   Phase 2   NCT00647946   United Kingdom;
Abacavir sulfate
   Glaxo Wellcome
      2000   Phase 4   NCT00005764   United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2002   -   NCT00028314   United States;
Abacavir sulfate, Lamivudine and Zidovudine
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 2   NCT00021463   United States;
Acetylcarnitine
   SIGMA-TAU
      2006   -   EUCTR2005-004665-42-IT   Italy;
Acipimox
   National Heart, Lung, and Blood Institute (NHLBI)
      2002   -   NCT00246402   United States;
Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene
   University Hospital, Bordeaux
      2014   -   NCT02056912   France;
Amprenavir
   Glaxo Wellcome
      1998   -   NCT00002417   United States;
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
Antiretroviral/Anti HIV
   Augusta University
      2020   Phase 4   NCT04340388   United States;
Aramchol
   University of California, San Diego
      2016   Phase 2   NCT02684591   United States;
Atazanavir
   BRISTOL-M.SQUIBB
      2005   -   EUCTR2004-002740-10-IT   Germany;Italy;Spain;United Kingdom;
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom;
Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)
   Bristol-Myers Squibb
      2005   Phase 4   NCT00135356   Canada;France;Germany;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Atazanavir (Reyataz)
   Clinical Alliance for Research & Education - Infectious Diseases, LLC.
      2006   Phase 4   NCT00426296   United States;
Atazanavir/Ritonavir
   National Institute of Allergy and Infectious Diseases (NIAID)
      2002   -   NCT00028314   United States;
Atorvastatin calcium
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00017758   United States;
Avandia administration for 6-12 weeks
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1999   Phase 1   NCT00006185   United States;
BMS-232632
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom;
Baricitinib
   Eli Lilly and Company
      2020   Phase 2/Phase 3   NCT04517253   Japan;
      2007   -   NCT01724580   United Kingdom;United States;
Berberine
   Hospital Civil de Guadalajara
      2021   Phase 3   NCT04860063   -
CD-4 guided therapy interruption
   Hospital Clinic of Barcelona
      2002   Phase 4   NCT00646984   Spain;
COMBIVIR
   University Hospital Birmingham
      2005   Phase 4   EUCTR2005-004021-26-GB   United Kingdom;
Caffeine
   University of Exeter
      2019   -   NCT04056000   United Kingdom;
Cholic Acid
   University of Texas Southwestern Medical Center
      2006   Phase 2   NCT00457639   United States;
Cofactor supplementation (thiamine, riboflavin, L-carnitine)
   Queen's University
      2002   Phase 4   NCT00202228   Canada;
Combivir (zidovudine [AZT] / lamivudine [3TC])
   Kirby Institute
      2004   Phase 4   NCT00192621   Australia;
Continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
   Bristol-Myers Squibb
      2005   Phase 4   NCT00135356   Canada;France;Germany;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Cyclophosphamide
   Children's Hospital of Fudan University
      2019   -   NCT03936829   China;
Didanosine
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
Different HAART regimens
   Danish HIV Research Group
      2004   Phase 4   NCT00139178   Denmark;
Diosminex, 500 mg, tabletki powlekane
   ALIO MEDICA Sp. z o.o.
      2014   -   EUCTR2013-004539-57-PL   Poland;
Dolutegravir
   Augusta University
      2020   Phase 4   NCT04340388   United States;
Dolutegravir / Lamivudine Oral Tablet
   Thomas Benfield
      2020   Phase 4   NCT04904406   Denmark;
Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]
   Thomas Benfield
      2021   Phase 4   NCT04903847   Denmark;
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
   Thomas Benfield
      2021   Phase 4   NCT04903847   Denmark;
Efavirenz
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 2   NCT00021463   United States;
      2001   Phase 1   NCT00017758   United States;
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 4   NCT00006190   United States;
   University Hospital Birmingham
      2005   Phase 4   EUCTR2005-004021-26-GB   United Kingdom;
   University of Texas Southwestern Medical Center
      2002   Phase 4   NCT00457665   United States;
Efavirenz (EFV)
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
Emtricitabine/tenofovir
   University Hospital Birmingham
      2005   Phase 4   EUCTR2005-004021-26-GB   United Kingdom;
Enfuvirtide (T20)
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
Fenofibrate
   Baylor College of Medicine
      2004   -   NCT00246376   United States;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2000   Phase 3   NCT00006412   Puerto Rico;United States;
GSK1265744B (sodium salt) containing 14C-GSK1265744B
   ViiV Healthcare
      2013   Phase 1   NCT01848340   United States;
Gemcabene
   Elif Oral
      2018   Phase 1/Phase 2   NCT03508687   United States;
Genotropin (human recombinant Growth hormone)
   Hvidovre University Hospital
      2005   Phase 4   NCT00119769   Denmark;
Glycerine
   Venus Concept
      2015   -   NCT02492997   United States;
Growth Hormone Releasing Hormone
   Massachusetts General Hospital
      2009   -   NCT00795210   United States;
High-carbohdyrate breakfast
   University of Exeter
      2019   -   NCT04056000   United Kingdom;
High-dose REGN4461
   Regeneron Pharmaceuticals
      2020   Phase 2   NCT04159415   Peru;Russian Federation;Turkey;United States;
Hu Leptin (A-100)
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 2   NCT00005905   United States;
Human recombinant leptin (metreleptin)
   Baylor College of Medicine
      2003   -   NCT01511016   United States;
ISIS 304801
   Akcea Therapeutics
      2016   Phase 2;Phase 3   EUCTR2015-000493-35-PT   Belgium;Brazil;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Akcea Therapeutics, Inc.
      2016   Phase 3   EUCTR2015-000493-35-DE   Belgium;Brazil;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   IONIS PHARMACEUTICALS, INC.
      2015   Phase 2;Phase 3   EUCTR2015-000493-35-IT   Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Ionis Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2015-000493-35-GR   Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000493-35-BE   Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Isis Pharmaceuticals, Inc.
      2015   Phase 3   EUCTR2015-000493-35-NL   Australia;Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 2;Phase 3   EUCTR2015-000493-35-ES   Australia;Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2015   Phase 2   NCT02639286   United States;
Indinavir
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
Kaletra (lopinavir [LPVr])
   Kirby Institute
      2004   Phase 4   NCT00192621   Australia;
Lamivudine
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 4   NCT00006190   United States;
Lamivudine/Zidovudine
   Glaxo Wellcome
      2000   Phase 4   NCT00005764   United States;
Leptin
   Beth Israel Deaconess Medical Center
      2006   Phase 2   NCT00362440   United States;
   Department of Medicine and Clinical Science, Kyoto University Graduate School of MedicineTranslational Research Center, Kyoto University Hospital
      2010   -   JPRN-UMIN000002818   Japan;
   Kyoto University Hospital
      2010   -   JPRN-UMIN000003679   Japan;
   University of Texas Southwestern Medical Center
      2006   Phase 2/Phase 3   NCT00896298   United States;
      2003   Phase 2   NCT00461552   United States;
Lopinavir/Ritonavir
   National Institute of Allergy and Infectious Diseases (NIAID)
      2002   -   NCT00028314   United States;
Lopinavir/ritonavir + nevirapine
   VU University Medical Center
      2003   Phase 4   NCT00122226   Finland;Netherlands;Spain;United Kingdom;
Lopinavir/ritonavir + zidovudine + lamivudine
   VU University Medical Center
      2003   Phase 4   NCT00122226   Finland;Netherlands;Spain;United Kingdom;
Low-Dose REGN4461
   Regeneron Pharmaceuticals
      2020   Phase 2   NCT04159415   Peru;Russian Federation;Turkey;United States;
Mecasermin
   University of Texas Southwestern Medical Center
      2011   Phase 1   NCT01329744   United States;
Metformin
   Tufts Medical Center
      2011   Phase 4   NCT01612858   United States;
Metformin hydrochloride
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   -   NCT00015691   United States;
Metreleptin
   Aegerion Pharmaceuticals, Inc.
      2018   Phase 4   NCT04026178   United States;
   Amryt Pharma
      2021   Phase 3   NCT05164341   -
   Bristol-Myers Squibb
      2008   -   NCT00677313   United States;
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2014   Phase 3   NCT02262832   United States;
      2014   Phase 2   NCT02262806   United States;
      2013   Phase 2   NCT01778556   United States;
      2001   Phase 2   NCT00025883   United States;
   University of Michigan
      2015   Phase 2   NCT02654977   United States;
      2012   Phase 2   NCT01679197   United States;
      2011   -   NCT02404896   United States;
Metrelpetin
   Medical University of Vienna
      2018   Phase 2   EUCTR2017-003014-22-AT   Austria;
Monotherapy (Lopinavir/ritonavir)
   Fundacion SEIMC-GESIDA
      2008   Phase 4   NCT00865007   Spain;
Monotherapy (Lopinavir/ritonavir) + ABC/3TC
   Fundacion SEIMC-GESIDA
      2008   Phase 4   NCT00865007   Spain;
Myalept
   Medical University of Vienna
      2018   Phase 2   EUCTR2017-003014-22-AT   Austria;
N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate
   Theratechnologies Inc.
      2007   Phase 3   EUCTR2007-003233-16-GB   Belgium;France;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005444-88-GB   Belgium;France;Germany;Spain;United Kingdom;
      2007   -   EUCTR2007-003233-16-FR   Belgium;France;Spain;United Kingdom;
      2007   -   EUCTR2007-003233-16-ES   Belgium;France;Spain;United Kingdom;
      2007   -   EUCTR2007-003233-16-BE   Belgium;France;Spain;United Kingdom;
      2007   -   EUCTR2006-005444-88-FR   France;Germany;Spain;United Kingdom;
      2007   -   EUCTR2006-005444-88-ES   France;Germany;Spain;United Kingdom;
      2007   -   EUCTR2006-005444-88-DE   France;Germany;Spain;United Kingdom;
      2007   -   EUCTR2006-005444-88-BE   Belgium;France;Germany;Spain;United Kingdom;
Nelfinavir
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
   University of Texas Southwestern Medical Center
      2002   Phase 4   NCT00457665   United States;
Nelfinavir mesylate
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00017758   United States;
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 4   NCT00006190   United States;
Nevirapine
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
   National Institute of Allergy and Infectious Diseases (NIAID)
      2002   -   NCT00028314   United States;
      2001   Phase 2   NCT00021463   United States;
Niacin
   Baylor College of Medicine
      2004   -   NCT00246376   United States;
Non-nucleoside reverse transcriptase inhibitors
   French National Agency for Research on AIDS and Viral Hepatitis
      2003   Phase 4   NCT00122668   France;
      2001   Phase 4   NCT00122655   France;
Norvir
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom;
NucleomaxX
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00119379   United States;
Nucleoside analogue sparing HAART regimen
   Danish HIV Research Group
      2003   Phase 4   NCT00135460   Denmark;
Perform blood cells and fibroblasts biochemical and immuno-labeled investigations
   University Hospital, Bordeaux
      2014   -   NCT02056912   France;
Pioglitazone
   French National Agency for Research on AIDS and Viral Hepatitis
      2003   Phase 3   NCT00148850   France;
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2005   -   NCT00656851   United States;
      2005   -   NCT00639457   United States;
   Tufts Medical Center
      2011   Phase 4   NCT01612858   United States;
   University of Texas Southwestern Medical Center
      2009   -   NCT01023620   United States;
Pioglitazone or metformin
   Beth Israel Deaconess Medical Center
      2006   Phase 2   NCT00362440   United States;
Pneumococcal polysaccharide vaccine 23 valent
   Medical University of South Carolina
      2015   Early Phase 1   NCT03039491   United States;
Pravastatin
   Kirby Institute
      2001   Phase 4   NCT00227500   Australia;
Pravastatin sodium
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00017758   United States;
      2000   Phase 3   NCT00006412   Puerto Rico;United States;
Prevenar13
   Maastricht University
      2016   Phase 4   EUCTR2015-004846-25-BE   Belgium;
Protease inhibitor
   French National Agency for Research on AIDS and Viral Hepatitis
      2003   Phase 4   NCT00122668   France;
Protease inhibitors
   French National Agency for Research on AIDS and Viral Hepatitis
      2001   Phase 4   NCT00122655   France;
R-metHuLeptin
   Beth Israel Deaconess Medical Center
      2001   Phase 2   NCT00140244   United States;
REGN4461
   Regeneron Pharmaceuticals
      2022   Phase 2   NCT05088460   -
      2021   -   NCT04710056   -
REYATAZ 150MG 60 CPS BL
   BRISTOL-M.SQUIBB
      2005   -   EUCTR2004-002740-10-IT   Germany;Italy;Spain;United Kingdom;
RTV
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom;
Raltegravir
   Southern California Institute for Research and Education
      2010   -   NCT01164605   United States;
   University of California, Los Angeles
      2008   Phase 2   NCT00656175   Canada;United States;
Recombinant human growth hormone
   Massachusetts General Hospital
      2004   -   NCT00100698   United States;
Recombinant human growth hormone + rosiglitazone
   Weill Medical College of Cornell University
      2005   Phase 1/Phase 2   NCT00130286   United States;
Reyataz
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom;
Ritonavir
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom;
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
Ritonavir (Norvir)
   Clinical Alliance for Research & Education - Infectious Diseases, LLC.
      2006   Phase 4   NCT00426296   United States;
Rosiglitazone maleate
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   -   NCT00015691   United States;
ST200
   SIGMA-TAU
      2006   -   EUCTR2005-004665-42-IT   Italy;
SUSTIVA
   University Hospital Birmingham
      2005   Phase 4   EUCTR2005-004021-26-GB   United Kingdom;
Saquinavir
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
Serostim®[somatropin (rDNA origin) for injection]
   EMD Serono
      2004   Phase 3   NCT00082628   Canada;United States;
Setmelanotide
   Rhythm Pharmaceuticals, Inc.
      2017   -   NCT03262610   United States;
Simvastatin
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00017758   United States;
Standard continuous antiretroviral therapy
   Hospital Clinic of Barcelona
      2002   Phase 4   NCT00646984   Spain;
Stavudine
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 4   NCT00006190   United States;
TAT4 Gel concentration A
   Topokine Therapeutics, Inc.
      2014   Phase 1   NCT02647853   United States;
TAT4 Gel concentration B
   Topokine Therapeutics, Inc.
      2014   Phase 1   NCT02647853   United States;
TH9507
   Theratechnologies
      2005   Phase 3   NCT00123253   Canada;United States;
   Theratechnologies Inc.
      2007   Phase 3   EUCTR2007-003233-16-GB   Belgium;France;Spain;United Kingdom;
      2007   Phase 3   EUCTR2006-005444-88-GB   Belgium;France;Germany;Spain;United Kingdom;
      2007   -   EUCTR2007-003233-16-FR   Belgium;France;Spain;United Kingdom;
      2007   -   EUCTR2007-003233-16-ES   Belgium;France;Spain;United Kingdom;
      2007   -   EUCTR2007-003233-16-BE   Belgium;France;Spain;United Kingdom;
      2007   -   EUCTR2006-005444-88-FR   France;Germany;Spain;United Kingdom;
      2007   -   EUCTR2006-005444-88-ES   France;Germany;Spain;United Kingdom;
      2007   -   EUCTR2006-005444-88-DE   France;Germany;Spain;United Kingdom;
      2007   -   EUCTR2006-005444-88-BE   Belgium;France;Germany;Spain;United Kingdom;
TRUVADA
   University Hospital Birmingham
      2005   Phase 4   EUCTR2005-004021-26-GB   United Kingdom;
Tenofovir
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
Tenofovir DF
   Gilead Sciences
      2003   Phase 2   NCT00647946   United Kingdom;
Tenofovir Disoproxil Fumarate
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00119379   United States;
Tesamorelin
   Columbia University
      2018   Phase 4   NCT03226821   United States;
   Massachusetts General Hospital
      2010   -   NCT01263717   United States;
   Theratechnologies
      2007   Phase 3   NCT00608023   Belgium;Canada;France;Spain;United Kingdom;United States;
   Theratechnologies Inc.
      2007   Phase 3   EUCTR2007-003233-16-GB   Belgium;France;Spain;United Kingdom;
      2007   -   EUCTR2007-003233-16-FR   Belgium;France;Spain;United Kingdom;
      2007   -   EUCTR2007-003233-16-ES   Belgium;France;Spain;United Kingdom;
      2007   -   EUCTR2007-003233-16-BE   Belgium;France;Spain;United Kingdom;
Tesamorelin (Egrifta)
   Johns Hopkins University
      2012   -   NCT01788462   United States;
Testosterone injection
   Queen's University
      1999   -   NCT00202241   Canada;
Tipranavir
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;
Total Dietary Replacement
   Cambridge University Hospitals NHS Foundation Trust
      2019   -   NCT03900286   -
Use of lipid-lowering drugs.
   University of Sao Paulo General Hospital
      2013   -   NCT02530827   -
VOLANESORSEN SODIUM, ApoC-III Antisense Oligonucleotide
   Akcea Therapeutics
      2016   Phase 2;Phase 3   EUCTR2015-000493-35-PT   Belgium;Brazil;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Akcea Therapeutics, Inc.
      2016   Phase 3   EUCTR2015-000493-35-DE   Belgium;Brazil;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   IONIS PHARMACEUTICALS, INC.
      2015   Phase 2;Phase 3   EUCTR2015-000493-35-IT   Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Ionis Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2015-000493-35-GR   Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 3   EUCTR2015-000493-35-BE   Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
   Isis Pharmaceuticals, Inc.
      2015   Phase 3   EUCTR2015-000493-35-NL   Australia;Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2015   Phase 2;Phase 3   EUCTR2015-000493-35-ES   Australia;Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Venus Versa
   Venus Concept
      2015   -   NCT02492997   United States;
Viral load driven treatment interruption
   Hospital Clinic of Barcelona
      2002   Phase 4   NCT00646984   Spain;
Volanesorsen
   Ionis Pharmaceuticals, Inc.
      2015   Phase 2/Phase 3   NCT02527343   Belgium;Brazil;Canada;Germany;Greece;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States;
Zidovudine
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia;